Malyarov 1999.

Methods	Allocation: randomised (no further description). Blindness: independent observers blind to treatment. Duration: 6 months. Consent: not stated. Setting: not stated.
Participants	Diagnosis: schizophrenia (ICD‐10). N=43. Age: mean ˜ 25 years. Sex: 28M, 15F. History: acute or post‐acute phase, hospitalised, duration of illness < 3 years. Exclusions: not stated.
Interventions	1. Risperidone: 3‐6mg/day. N=10. 2. Haloperidol: 5‐20mg/day. N=18. 3. Olanzapine: 5‐15mg/day. N=15.
Outcomes	Leaving the study early. Unable to use ‐ Global effect: (no data). Mental State: PANSS (no SD).
Notes	Conference abstract only. Only risperidone and haloperidol data used in this review.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear